HOME HELP FEEDBACK SUBSCRIPTIONS ALL ISSUES SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhukareva, V. Articles by Lee, V. M.-Y. Search for Related Content PubMed PubMed Citation Articles by Zhukareva, V. Articles by Lee, V. M.-Y.

Assessment of Pathological Tau Proteins in Frontotemporal Dementias

Qualitative and Quantitative Approaches

Received December 2, 2003; revised January 5, 2004; accepted January 8, 2004. From the Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine VZ,JQT,VM-YL) and the Institute on Aging, University of Pennsylvania (JQT). Address correspondence to: Virginia M.-Y. Lee, Ph.D., Center for Neurodegenerative Disease Research, Maloney 3, HUP, 3600 Spruce Street, Philadelphia, PA 19104-4283. e-mail: vmylee{at}mail.med.upenn.edu
© 2004 American Association for Geriatric Psychiatry

A large group of clinically and neuropathologically heterogeneous frontotemporal dementias (FTDs) is distinguished by the accumulation of filamentous tau proteins in neuronal and non-neuronal cells, and these disorders are collectively designated as tauopathies. Recent advances in the development of new reagents and the utilization of new multidisciplinary approaches have made substantial progress in the extensive characterization of tau proteins in different tauopathies. Until recently, semi-quantitative assessment of specific pathological lesions in FTDs was limited to immunohistochemical methods. However, it has become increasingly evident that biochemical analyses of pathological tau proteins in diseased brains also play a significant role in establishing the diagnosis of specific FTD subtypes. In this review, the authors summarize recent findings of the unique biochemical tau signatures for a number of specific tauopathies. Moreover, the quantitative assessment of abnormal tau proteins described here reveals heterogeneity in the biochemical features of tau pathologies in FTDs. The identification of highly insoluble tau species that may be more prone to physiological clearance, other than those that form paired helical filaments, could provide additional insights into the role of tau in mechanisms of neurodegeneration in FTDs.

Key Words: Pathological Tau Proteins • Frontotemporal Dementias

This article has been cited by other articles:

				M. S. Forman, E. J. Mufson, S. Leurgans, D. Pratico, S. Joyce, S. Leight, V. M.-Y. Lee, and J. Q. Trojanowski Cortical biochemistry in MCI and Alzheimer disease: Lack of correlation with clinical diagnosis Neurology, March 6, 2007; 68(10): 757 - 763. [Abstract] [Full Text] [PDF]

				N. Shahani, S. Subramaniam, T. Wolf, C. Tackenberg, and R. Brandt Tau aggregation and progressive neuronal degeneration in the absence of changes in spine density and morphology after targeted expression of Alzheimer's disease-relevant tau constructs in organotypic hippocampal slices. J. Neurosci., May 31, 2006; 26(22): 6103 - 6114. [Abstract] [Full Text] [PDF]

				S. E. Arnold Bedside to Bench and Back Again: Translational Neuroscience Research and Geriatric Psychiatry Am J Geriatr Psychiatry, April 1, 2004; 12(2): 122 - 125. [Full Text] [PDF]